TD Cowen analyst Tyler Van Buren has maintained their bullish stance on BCAX stock, giving a Buy rating on March 27.
Tyler Van Buren has given his Buy rating due to a combination of factors including the promising data expected from Bicara Therapeutics Inc.’s upcoming presentations and trials. The company is set to present data from a cSCC cohort, where the monotherapy activity of their product, Ficera, is anticipated to be evident. Additionally, the forthcoming two-year survival data from the Phase Ib trial involving a combination with pembro could significantly reduce the risk associated with the ongoing pivotal trial.
Ficera, a bifunctional antibody, targets both EGFR and TGF-β at the tumor site, addressing key resistance mechanisms and potentially offering more potent and durable responses. The initial dose expansion trial showed impressive results, particularly in HPV- patients, with a high overall response rate and notable complete response rate. This suggests a durable progression-free survival benefit compared to existing treatments, which supports the positive outlook and Buy rating for the stock.
In another report released on March 27, Morgan Stanley also maintained a Buy rating on the stock with a $36.00 price target.